ANAPTYSBIO, INC 8-K

What Happened
AnaptysBio filed an 8-K reporting that First Tracks Biotherapeutics (the spun-off company, “SpinCo”) entered a March 26, 2026 purchase agreement to sell Primary Shares in a private placement and that AnaptysBio will distribute SpinCo shares to its stockholders as a spin-off. The Private Placement covers 5,791,478 primary shares and 4,705,576 secondary shares at $13.81 per share; First Tracks is expected to receive approximately $80 million of gross proceeds from the sale of the primary shares. The spin-off distribution (one SpinCo share per AnaptysBio share) has a record date of April 6, 2026 and is expected to be distributed prior to market open on April 20, 2026, when SpinCo common stock is expected to begin trading on Nasdaq under the ticker “TRAX.”

Key Details

• Private Placement price: $13.81 per share; Primary Shares: 5,791,478; Secondary Shares: 4,705,576.
• Expected gross proceeds to First Tracks from Primary Shares: ~ $80 million (before expenses). First Tracks receives no proceeds from the Secondary Shares.
• Spin-off timing: record date April 6, 2026; distribution and expected Nasdaq listing April 20, 2026. Investors will receive 1 SpinCo share per AnaptysBio share held on the record date.
• Closing of the Private Placement is conditioned on SpinCo Form 10 registration effectiveness, completion of the separation, Nasdaq listing, absence of material adverse effect, and other customary conditions. SpinCo will grant investors registration rights requiring a resale registration within 45 days after closing.
• AnaptysBio terminated its ATM Sales Agreement with TD Securities (entered Nov 5, 2024); no further sales under that program.
• Governance and personnel: Susannah Gray was appointed Class I director (granted pro rata retainer and 11,250 RSUs vesting over three years). Executive transitions: Dennis Mulroy and Eric Loumeau entered separation agreements effective on the spin-off date, each receiving a lump sum equal to nine months’ base pay and COBRA reimbursement for nine months; both are expected to have post-spin-off consulting arrangements.

Why It Matters
The filing details the formal steps for separating SpinCo as a publicly traded company and securing initial financing for First Tracks through a private placement. For AnaptysBio shareholders, the spin-off will deliver direct ownership of SpinCo (ticker TRAX) and could change AnaptysBio’s capital structure and focus after distribution. The private placement provides First Tracks with immediate capital (~$80M gross) but also imposes customary closing and registration conditions that could affect timing. The termination of the ATM program removes a prior avenue for AnaptysBio to raise capital via at-the-market sales. Director and executive transitions introduce short-term cash outlays (severance) and governance changes ahead of the separation.